World Monitor Mag, Industrial Overview WM_November_2018_WEB_Version - Page 35

EXPERT OPINION of the country's economy; secondly, we do not just supply medicines, being the flagship of domestic pharmaceutical in- dustry, but also we are reliable partners of the Ministry of Health for promising projects that are important for the de- velopment of domestic healthcare. For example, last year alone, together with the Republican Centre for Health Develop- ment of the Ministry of Health of RK, we held a series of seminars featuring par- ticipation of an international expert on the evaluation of medical technologies. It is rather difficult to develop an expert service, since this task requires signifi- cant investments. Our initiative has be- come a popular partner project, covering the most current direction. Speaking about the scale of SANTO, you mentioned the plant in Shymkent. We know that the company is making investments in its development. How do you think the investments improve the work of the enterprise and what are the achievements? I would like to note that the plant in Shymkent is probably the most modern pharmaceutical site in the country. It is quite unique, because there are productions there that have no analogues throughout the Central Asian region. Since 2011, from the date of the investor’s arrival, the company does not actually have a single old production site left. Starting in 2014, almost every year, we launch new production in accordance with the standards of good manufacturing practice cGMP. Today, the plant has six production zones: injectables in ampoules; infusion preparations in bottles; two production of powder antibiotics; the production of solid dosage forms and another new project that we launched this spring is the production of non-sterile solutions. Imagine that in a territory of 17 hectares completely different areas are concentrated. All specified production lines are new projects that have been completed because of the investments of the Polpharma Group. The construction and modernization of sites required an $84 million investment, infrastructure preparation, excluding the costs of personnel training, technology transfer, and the introduction of standards. Today the plant is not only new production, but first of all people who receive advanced experience here. Now we are in the sixth stage of the investment program, which by 2023 could exceed $108 million. In 2019, we are planning to create a new site for the production of solid dosage forms using wet granulation. We already have a new solid drugs production plant that we launched last year, but a different technology is being used there. A huge laboratory modernization project has been planned. The existing modern laboratory of the scientific research institute was created during the first stage of the investment program. We are starting a project to create and modernize a microbiology and quality control laboratory complex. This is also an investment project that supported by EUROBAK 33